15:38 , Aug 17, 2018 |  BC Extra  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for the...
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
22:42 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified tetrahydrophthalazinone-based inhibitors of T. brucei PDEB1 that could help treat African trypanosomiasis. Chemical synthesis and in vitro activity and cell division assays of tetrahydrophthalazinone analogs yielded two compounds that...
23:30 , May 7, 2018 |  BC Extra  |  Preclinical News

CRISPR platforms edit genome-wide at single-base level

Two studies in Nature Biotechnology describe CRISPR-Cas9-based techniques can produce trackable edits at single nucleotide resolution in eukaryotic cells. The methods stand to make genetic screens more precise and efficient. In eukaryotic cells, double-stranded DNA...
23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously identified...
20:47 , Feb 9, 2018 |  BC Extra  |  Company News

Novo gains European approval for diabetes drug Ozempic

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said the European Commission approved subcutaneous Ozempic semaglutide (NN9535) to treat Type II diabetes in adults. Novo plans to launch the therapy next half. The product is indicated for use...
21:14 , Dec 14, 2017 |  BC Innovations  |  Emerging Company Profile

Backpacks for CARs

Torque Therapeutics Inc. is making “backpacks” for immune cell therapies that release immune stimulatory molecules at particular doses and locations to boost the cells’ activity without risking systemic exposure. The technology could augment the success...
04:16 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

FDA approves Novo Nordisk's subcutaneous Ozempic semaglutide for diabetes

FDA approved subcutaneous Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. Novo Nordisk plans to launch the long-acting glucagon-like...
23:27 , Dec 5, 2017 |  BC Extra  |  Company News

FDA approves Novo Nordisk's semaglutide for diabetes

FDA approved subcutaneous Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. Novo Nordisk plans to launch the long-acting glucagon-like...
00:28 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

FDA panel backs approval of Novo's semaglutide

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0 with 1 abstention that safety and efficacy data support approval of subcutaneous semaglutide (NN9535) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). The long-acting glucagon-like peptide-1 (GLP-1) analog...